RecruitingNCT07152119
A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
KOREAN POST MARKETING SURVEILLANCE FOR LITFULO CAPSULE
Sponsor
Pfizer
Enrollment
3,000 participants
Start Date
Aug 27, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this observation study is to learn about the safety and effects of the study medicine (called Litfulo) for the potential treatment of Severe Alopecia Areata.
Eligibility
Min Age: 12 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called Litfulo for people with severe alopecia areata. The study is currently recruiting participants at 1 location. People eligible for this study include aged 12 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLitfulo
as provided in real world practice.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07152119
Related Trials
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT0702982841 locations
Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose Administration, and in Non-segmental Vitiligo Patients and Alopecia Areata Patients After Multiple-dose Administration
NCT075542221 location
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT0702971180 locations